Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01269710 · ClinicalTrials.gov registry record
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 4
- Enrollment target
NCT01269710: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT01269710 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01269710 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents. The study's primary aim is to identify genetic risk factors for weight gain and metabolic abnormalities.
Primary Outcome
Participants will be evaluated for biological and genetic risk factors for nutritional and metabolic adverse effects associated with second-generation antipsychotics (SGA's) during 4 visits over 12 weeks. Participants will also be evaluated at Month 6, 9, and 12 (Week 52). Since only a single participant finished the study and had assessments through Week 52, we compiled the data from all subject endpoints (1 Week 12 visit, 2 Week 36 visits, and 1 Week 52 visit) and this is the data reported be
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-03 |
What the finished NCT01269710 record still lists
NCT01269710 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01269710 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01269710 about?
NCT01269710 is a clinical study titled "Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study". The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents. The study's primary aim is to identify genetic risk factors for weight gain and metabolic abnormalities.
What is the current status of trial NCT01269710?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2009-10. Estimated completion is 2011-03.
Who is sponsoring clinical trial NCT01269710?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia